That sales dropping from $19m to $10 mil is surprising. I realize there is pipeline fill in the first quarter, however you would expect that the turnover and new orders would at least keep them in the ballpark. Clearly the market is discounting the CV revenues and thinking this may be a downward trend.
As any large shareholder would appreciate, the need to use this positive cash position to pull out all the stops to get AI moving is critical to the companies success.
I agree with the posters who are calling out M.G. Talk is cheap and not too many of us are still in the third grade and don't appreciate being treated or talked to that way.
Question: Is there some significance around $0.18c ? I have lost track but I recall someone posting there was a financial activity around this number?
JMHO
| | Q1 2021 | Q1 2020 | % Change |
| Total revenues | $19,045,888 | $809,402 | 2,253% |
| COVID-19 Test kits revenue | $18,561,296 | $0 | 100% |
| AI and Technology and Other revenue | $484,592 | $809,402 | -40% |
| Income/Loss before income taxes | $10,482,954 | (737,968) | 1,521% |
| Net Income/Loss | $9,560,351 | (721,761) | 1,425% |
| Income per share - basic | $0.03 | (0.003) | 1,100% |
| EBITDA | $10,684,254 | ($737,698) | 1,548% |
The following reconciles the net income, EBITDA and Adjusted EBITDA (non-IFRS):
| | Q1 2021 | Q1 2020 |
| | March 31, 2021 | March 31, 2020 |
| Net profit | $9,560,351 | ($721,761) |
| Add: interest and accretion | $10,936 | $14,766 |
| Add: income tax provisions (recovery) | $922,603 | ($16,207) |
| Add: depreciation & amortization | $190,364 | $194,899 |
| EBITDA (non IFRS) | $10,684,254 | ($528,303) |
| Add: share based compensation | $3,268,404 | $271,000 |
| Adjusted EBITDA (non IFRS) | $13,952,658 | ($257,303) |
| | Q1 2021 | Q1 2020 | Dollar Change | Percent Change |
| Total Assets | $25,026,759 | $9,998,329 | $15,028,430 | 150% |
| Total Liabilities | $6,467,940 | $6,053,667 | $414,273 | 7% |
The following presents Book value per share ("BVPS"). Please refer to the note at the end of this news release concerning non-IFRS financial measures.
| | Q1 2021 | Q1 2020 |
| Equity Attributable to DM Shareholders (book value) | $17,863,877 | $2,473,792 |
| Total common shares outstanding at period end | 292,769,034 | 233,701,561 |
| BVSP | $0.06 | $0.01 |
| | Q1 2021 | Q1 2020 | % Change |
| Total revenues | $19,045,888 | $809,402 | 2,253% |
| COVID-19 Test kits revenue | $18,561,296 | $0 | 100% |
| AI and Technology and Other revenue | $484,592 | $809,402 | -40% |
| Income/Loss before income taxes | $10,482,954 | (737,968) | 1,521% |
| Net Income/Loss | $9,560,351 | (721,761) | 1,425% |
| Income per share - basic | $0.03 | (0.003) | 1,100% |
| EBITDA | $10,684,254 | ($737,698) | 1,548% |
The following reconciles the net income, EBITDA and Adjusted EBITDA (non-IFRS):
| | Q1 2021 | Q1 2020 |
| | March 31, 2021 | March 31, 2020 |
| Net profit | $9,560,351 | ($721,761) |
| Add: interest and accretion | $10,936 | $14,766 |
| Add: income tax provisions (recovery) | $922,603 | ($16,207) |
| Add: depreciation & amortization | $190,364 | $194,899 |
| EBITDA (non IFRS) | $10,684,254 | ($528,303) |
| Add: share based compensation | $3,268,404 | $271,000 |
| Adjusted EBITDA (non IFRS) | $13,952,658 | ($257,303) |
| | Q1 2021 | Q1 2020 | Dollar Change | Percent Change |
| Total Assets | $25,026,759 | $9,998,329 | $15,028,430 | 150% |
| Total Liabilities | $6,467,940 | $6,053,667 | $414,273 | 7% |
The following presents Book value per share ("BVPS"). Please refer to the note at the end of this news release concerning non-IFRS financial measures.
| | Q1 2021 | Q1 2020 |
| Equity Attributable to DM Shareholders (book value) | $17,863,877 | $2,473,792 |
| Total common shares outstanding at period end | 292,769,034 | 233,701,561 |
| BVSP | $0.06 | $0.01 |